ホーム › びまん性大細胞型B細胞リンパ腫 › ニュージャージー
ニュージャージーにおけるびまん性大細胞型B細胞リンパ腫の臨床試験
ニュージャージー内の拠点で、びまん性大細胞型B細胞リンパ腫に関する13件の研究が参加者を募集しています。
ニュージャージー内の都市
公式研究テキスト（英語）
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Atlantic Health Morristown Medical Center ( Site 0163), Morristown
- Valley Health Systems - Ridgewood Campus ( Site 0125), Paramus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Rutgers Cancer Institute of New Jersey, New Brunswick
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Rutgers Cancer Institute of New Jersey, New Brunswick
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Astera Cancer Care, East Brunswick
- John Theurer Cancer Center, Hackensack
- Rutgers Cancer Institute of New Jersey, New Brunswick
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Hackensack, Hackensack
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START New Jersey, East Brunswick
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Hackensack Meridian Health (Data collection only), Hackensack
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- 他1件
被験者募集中第2相
65歳〜80歳 · 全性別 · 2026/07/22更新 · NCT06765317SynKIR-310 for Relapsed/Refractory B-NHL
- Rutgers Cancer Institute, New Brunswick
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/14更新 · NCT06544265Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/02/17更新 · NCT04512716A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/18更新 · NCT06736613Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Hackensack University Medical Center, Hackensack
被験者募集中第2相
18歳以上 · 全性別 · 2024/09/26更新 · NCT06238648ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。